Metabolic syndrome (MetS) is a health disorder characterized by metabolic abnormalities that predict an increased risk to develop cardiovascular disease (CVD) and type 2 diabetes. Biomarkers can provide an insight into the novel mechanism for MetS and can be potentially used for personalized response to therapies. We exploited a targeted HPLC-MS/MS method to characterize plasma amino acids and carnitine metabolic profile in MetS patients. A training set (40 cases and 40 controls) and validation set (80 MetS patients and 80 healthy controls) were carried out to find the metabolic profiles. We discovered two carnitine metabolites including hydroxydecanoyl carnitine and methylglutarylcarnitine. Our results indicated that the decreased level of hydroxydecanoyl carnitine and methylglutarylcarnitine may be associated with the risk of MetS. These biomarkers may improve the risk prediction and provide a novel tool for monitoring of the progression of disease and response to treatment in MetS patients.

中文翻译：

---

使用HPLC-MS / MS对代谢综合征患者的血浆氨基酸和肉碱进行靶向代谢组学

代谢综合症（MetS）是一种以代谢异常为特征的健康疾病，可预测发生心血管疾病（CVD）和2型糖尿病的风险增加。生物标记物可以提供对MetS新型机制的深入了解，并可以潜在地用于对疗法的个性化反应。我们利用靶向HPLC-MS / MS方法表征MetS患者的血浆氨基酸和肉碱代谢特征。进行了一个训练集（40例和40个对照）和验证集（80个MetS患者和80个健康对照）以发现代谢谱。我们发现了两种肉碱代谢产物，包括羟基癸酰肉碱和甲基戊二酰肉碱。我们的结果表明，羟癸酰肉碱和甲基戊二酰肉碱水平的降低可能与MetS的风险有关。